PMID- 24041628
OWN - NLM
STAT- MEDLINE
DCOM- 20140808
LR  - 20131230
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 89
IP  - 1
DP  - 2014 Jan
TI  - Drug interactions with solid tumour-targeted therapies.
PG  - 179-96
LID - S1040-8428(13)00184-4 [pii]
LID - 10.1016/j.critrevonc.2013.08.007 [doi]
AB  - Drug interactions are an on-going concern in the treatment of cancer, especially 
      when targeted therapies, such as tyrosine kinase inhibitors (TKI) or mammalian 
      target of rapamycin (mTOR) inhibitors, are being used. The emergence of elderly 
      patients and/or patients with both cancer and other chronic co-morbidities leads 
      to polypharmacy. Therefore, the risk of drug-drug interactions (DDI) becomes a 
      clinically relevant issue, all the more so as TKIs and mTOR inhibitors are 
      essentially metabolised by cytochrome P450 enzymes. These DDIs can result in 
      variability in anticancer drug exposure, thus favouring the selection of 
      resistant cellular clones or the occurrence of toxicity. This review provides a 
      comprehensive overview of DDIs that involve targeted therapies approved by the 
      FDA for the treatment of solid tumours for more than 3 years (sorafenib, 
      sunitinib, erlotinib, gefitinib, imatinib, lapatinib, everolimus, temsirolimus) 
      and medicinal herb or drugs. This review also provides some guidelines to help 
      oncologists and pharmacists in their clinical practice.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Thomas-Schoemann, Audrey
AU  - Thomas-Schoemann A
AD  - Centre d'Etude et de Recours aux Inhibiteurs de l'Angiogenese, Paris, France; UF 
      de Pharmacocinetique et Pharmacochimie, Groupement des Hopitaux Paris Centre, 
      75014 Paris, France. Electronic address: schoemann.audrey@gmail.com.
FAU - Blanchet, Benoit
AU  - Blanchet B
AD  - Centre d'Etude et de Recours aux Inhibiteurs de l'Angiogenese, Paris, France; UF 
      de Pharmacocinetique et Pharmacochimie, Groupement des Hopitaux Paris Centre, 
      75014 Paris, France.
FAU - Bardin, Christophe
AU  - Bardin C
AD  - UF de Pharmacocinetique et Pharmacochimie, Groupement des Hopitaux Paris Centre, 
      75014 Paris, France.
FAU - Noe, Gaelle
AU  - Noe G
AD  - UF de Pharmacocinetique et Pharmacochimie, Groupement des Hopitaux Paris Centre, 
      75014 Paris, France.
FAU - Boudou-Rouquette, Pascaline
AU  - Boudou-Rouquette P
AD  - Centre d'Etude et de Recours aux Inhibiteurs de l'Angiogenese, Paris, France; 
      Service d'Oncologie Medicale, Groupement des Hopitaux Paris Centre, AP-HP, Paris, 
      France.
FAU - Vidal, Michel
AU  - Vidal M
AD  - Centre d'Etude et de Recours aux Inhibiteurs de l'Angiogenese, Paris, France; UF 
      de Pharmacocinetique et Pharmacochimie, Groupement des Hopitaux Paris Centre, 
      75014 Paris, France; UMR 8638 CNRS, UFR des Sciences Pharmaceutiques et 
      Biologiques, Universite Paris Descartes, Sorbonne Paris Cite, 75270 Paris, 
      France.
FAU - Goldwasser, Francois
AU  - Goldwasser F
AD  - Centre d'Etude et de Recours aux Inhibiteurs de l'Angiogenese, Paris, France; 
      Service d'Oncologie Medicale, Groupement des Hopitaux Paris Centre, AP-HP, Paris, 
      France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130828
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/classification/*therapeutic use
MH  - Drug Interactions
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Neoplasms/*drug therapy
OTO - NOTNLM
OT  - 5-fluorouracile
OT  - 5FU
OT  - ABC
OT  - ATP-binding cassette
OT  - AUC
OT  - BCRP
OT  - C(max)
OT  - CYP
OT  - DDI
OT  - Drug-drug interactions
OT  - EIAEDS
OT  - Herb-drug interactions
OT  - Mammalian target of rapamycin inhibitors
OT  - P-glycoprotein
OT  - P-gp
OT  - Pharmacokinetics
OT  - Solid tumour
OT  - TKI
OT  - Targeted therapies
OT  - Tyrosine kinase inhibitors
OT  - UDP-glucuronyl transferase
OT  - UGT
OT  - area under the curve
OT  - breast cancer resistance protein
OT  - cytochrome p450 enzymes
OT  - drug-drug interactions
OT  - enzyme-inducing antiepileptic drugs
OT  - mTOR
OT  - mammalian target of rapamycin
OT  - maximum (peak) plasma concentration
OT  - tyrosine kinase inhibitor
EDAT- 2013/09/18 06:00
MHDA- 2014/08/13 06:00
CRDT- 2013/09/18 06:00
PHST- 2013/03/25 00:00 [received]
PHST- 2013/07/11 00:00 [revised]
PHST- 2013/08/16 00:00 [accepted]
PHST- 2013/09/18 06:00 [entrez]
PHST- 2013/09/18 06:00 [pubmed]
PHST- 2014/08/13 06:00 [medline]
AID - S1040-8428(13)00184-4 [pii]
AID - 10.1016/j.critrevonc.2013.08.007 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 
      10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28.